How do biosimilar developers recruit patients for clinical trials?
Biosimilar trials often recruit the same types of patients clinicians already treat with the reference biologic, because the goal is to demonstrate similarity in key outcomes (pharmacokinetics, pharmacodynamics, and/or clinical endpoints) rather than to test a brand-new disease population. Recruitment plans typically focus on:
- Patients who are already eligible for the reference product under standard-of-care criteria (or patients naïve to the therapy, when the protocol requires it).
- Sites with high patient volume for the target indication, so recruitment can meet timelines.
- Clear eligibility checklists aligned with the reference product’s labeled use patterns and the trial protocol’s inclusion/exclusion criteria.
What recruitment tactics work best at trial sites?
Common site-level strategies include:
- Partnering with large outpatient infusion centers and specialty clinics that regularly administer the biologic.
- Using investigator networks and referral pathways from treating specialists (oncology, rheumatology, gastroenterology, etc., depending on the product).
- Training site coordinators and research staff to screen quickly and document eligibility consistently, since biologic protocols frequently include multiple lab, disease-activity, and prior-therapy constraints.
How do sponsors use databases, outreach, and advertising without breaking rules?
Recruitment is usually a mix of direct outreach and governed advertising. Sponsors and CROs commonly use:
- Centralized patient databases used for trial matching (where permitted) to identify potentially eligible patients.
- Community outreach and informational materials that describe trial purpose, requirements, and risks in plain language.
- Social media and digital campaigns in jurisdictions that allow them, coordinated with local regulations and ethics boards.
The most effective campaigns tend to target the exact eligibility profile (diagnosis, prior treatment history, treatment setting), not just the disease broadly, because biologic biosimilar trials can be narrow.
What role do patient assistance programs and support services play?
Even when a trial does not pay standard medical costs, patients may face practical barriers (travel, time off work, monitoring frequency). Sponsors often reduce drop-off by offering:
- Help with scheduling and transport logistics where allowed.
- Clear explanations of study visits, monitoring, and what happens if the patient discontinues.
- Assistance navigating insurance coverage questions for routine care versus trial-related procedures.
These supports can materially improve screening-to-enrollment conversion, especially for studies with longer observation periods.
Do trials recruit “switch” patients, and how does that change enrollment?
Some biosimilar programs involve switching or evaluating outcomes after patients move from the reference product to the biosimilar. Recruitment strategy then has to address:
- How patients were previously treated (must they already be on the reference product? for how long?).
- Consent messaging that explains interchangeability assumptions (where relevant) versus what the protocol actually tests.
- Additional attention to patient expectations, because some patients associate “switching” with uncertainty.
When switching is required, sponsors often prioritize sites with steady reference-product utilization to find eligible candidates faster.
How do endpoints and trial design affect who can enroll?
Recruitment friction rises when eligibility depends on tightly defined clinical features that are not routinely documented in everyday care. Sponsors can improve enrollment by:
- Ensuring screening criteria match routinely collected clinical data at sites.
- Allowing a practical window for baseline labs and disease-activity measures.
- Planning for confirmatory testing at screening to avoid screen failures later.
If the protocol uses pharmacokinetic or immunogenicity sampling schedules, sites also need staffing and lab capacity—otherwise enrollment slows.
What are common barriers to biosimilar enrollment?
Patients and sites may face:
- Prior biologic exposure rules that exclude otherwise eligible patients.
- Immunogenicity screening requirements or constraints on concomitant medications.
- Concerns about safety, efficacy, and whether the biosimilar can be “switched” outside the study.
- Competition for patients from other studies, especially in high-demand therapeutic areas.
Sponsors typically respond with tighter pre-screening, clearer patient materials, and rapid investigator screening workflow to reduce avoidable screen failures.
How does competition with other trials influence strategy?
In crowded indications, recruitment often depends on differentiating the study’s practical burden and patient value. Effective approaches include:
- Recruiting early in the indication’s seasonal treatment cycles (when patients initiate therapy or have more routine visits).
- Coordinating with sites so patients are approached consistently and ethically without “overlapping” study recruiters creating confusion.
- Adjusting campaign timing to when specialists see most eligible patients.
What should you look at if you’re studying recruitment performance?
If you’re evaluating recruitment strategies (for a sponsor, CRO, or site), useful metrics include:
- Screening-to-enrollment ratio (how many screened patients pass criteria).
- Time from first patient in site to first enrollment.
- Patient retention and discontinuation reasons (e.g., adverse events, convenience/visit burden, protocol changes).
- Site activation timelines and reasons for slow activation (staffing, IRB/ethics approvals, lab setup).
DrugPatentWatch.com can also help track biosimilar development timelines and product candidates, which is useful when mapping recruitment windows to expected trial activity (and competitors in the same area) [1].
Sources
- DrugPatentWatch.com